Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › METROPOLIS

METROPOLIS

Metropolis Healthcare Limited
Micro-capPharma ↗

What the six lenses say about METROPOLIS — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹577.8
2026-09-08
VWAP · 1Y anchor
₹517
+11.8% from VWAP
P/E · TTM
63.0×
TTM EPS ₹9.2
52-week range
89%
position low→high
RSI(14)
53
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How METROPOLIS’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
7.5
avg conviction decile
Leadership
—
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Micro-cap cohortDRaw
TechnicalD890›

The actual numbers

Price vs VWAP (1y)+11.8%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+10.8%
Price vs 50-EMA+2.6%
RSI(14)53
RS vs Nifty 500 · 3M+4.7%
RS vs sector · 3M-1.4%
52-week range89%
Volume vs 30d avg1.03×
Volume vs 60d avg0.98×
ATR(14) · volatility17.6
Bollinger width · vol contraction0.108
FundamentalD962›

The actual numbers

Return on equity (ROE)12.6%
Operating margin17.3%
Net margin11.6%
Revenue growth · YoY+23.7%
EPS growth · YoY-61.8%
Debt / equity0.15×

Full 8-quarter history in the financials table below.

ValuationD10›

The actual numbers

P/E (TTM)63.0×
TTM EPS₹9.2
52-week range89%
CatalystD638›

The actual numbers

Earnings & momentum31
Capital actions21
Governance108

Every filing in the corporate-announcements panel below.

FlowD758›

The actual numbers

Promoter holding48.9%
Delivery · 30d avg53.9%
Up/down-day asymmetry4.3pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Micro-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D8 + D7 ) ÷ 2 = 7.5(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
87
Conviction score 87/100 · avg-decile strength 7.5/10
Conviction score87/100›
TechnicalD8›
FundamentalD9›
ValuationD1›
CatalystD6›
FlowD7›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
-1.4pp
+0.5pp
+5.8pp
+6.2pp
+31.8pp
+11.4pp
Nifty 500
Broad-market baseline
-1.4pp
+0.5pp
+4.7pp
+4.7pp
+26.1pp
+6.1pp
Sector
Own-sector index
—
—
+1.9pp
-1.4pp
+12.9pp
-14.7pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

METROPOLIS daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
577.75-10.95

Relative strength

RS vs baseline · rebased to 100

METROPOLIS ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
108.91-1.60

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)313350323345386429406425
↳ change QoQ—+11.6%-7.7%+6.9%+11.9%+11.1%-5.4%+4.7%
EBITDA (₹cr)819375629010895108
EBITDA margin25.9%26.6%23.1%18.0%23.3%25.2%23.4%25.4%
PAT (₹cr)3847312945534251
↳ change QoQ—+22.5%-32.6%-7.9%+55.2%+17.8%-20.8%+21.4%
Net margin12.2%13.4%9.8%8.4%11.7%12.3%10.3%12.0%
EPS (₹)7.419.086.111.412.172.542.002.46
D/E————————
YoY growth · Mar '26Revenue +23.2% YoYPAT +75.9% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 9 Sep '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 7 Sep '26
    LOWgovernance
    Other Restructuring
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 2 Sep '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 27 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 27 Aug '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 27 Aug '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 20 Aug '26
    LOWgovernance
    Sale or disposal
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 20 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 10 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 5 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 4 Aug '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 4 Aug '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 4 Aug '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 4 Aug '26
    LOWgovernance
    Options to purchase securities
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 4 Aug '26
    LOWgovernance
    Allotment of Securities
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds METROPOLIS

Mutual funds holding METROPOLIS (10)

FundWeightAUM ₹crGrade
Aditya BSL Flexi Cap Gr0.58%28,112
HDFC Hybrid Eq Gr0.63%22,521
Kotak Small Cap Reg Gr1.96%18,933
HDFC ELSS TaxSaver Gr1.16%16,095
Franklin India Small Cap Gr1.76%14,467
Canara Robeco Small Cap Reg Gr1.23%14,231
UTI Large cap Reg Gr0.94%12,303
Aditya BSL Multi-Cap Reg Gr0.68%7,182
ICICI Pru Pharma Healthcare Diag Gr1.49%6,803
UTI Small Cap Reg Gr1.11%5,263

ETFs holding METROPOLIS (0)

No tracked ETF holds METROPOLIS ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma